International Clinical Trial: Epidemiology, Risk Factors, and Efficacy and Safety of Aztreonam-Avibactam for Complicated Intra-abdominal Infections (cIAI), Hospital-Acquired Pneumonia (HAP), and Ventilator-Associated Pneumonia (VAP) Caused by Carbapenem-Resistant Enterobacteriaceae in Critically Ill Adult Patients in China

Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (ChiCTR2600133607) titled 'Epidemiology, Risk Factors, and Efficacy and Safety of Aztreonam-Avibactam for Complicated Intra-abdominal Infections (cIAI), Hospital-Acquired Pneumonia (HAP), and Ventilator-Associated Pneumonia (VAP) Caused by Carbapenem-Resistant Enterobacteriaceae in Critically Ill Adult Patients in China' on Sept. 29.

Study Type: Observational study

Study Design: Cohort study

Primary Sponsor: The First Affiliated Hospital,Sun Yat-sen University

Condition: Resistance to carbapenem-resistant Enterobacteriaceae infections

Intervention: Treatment with non-aztreonam avibactam(Prospective section):None Treatment with aztreo...